Reports Q1 revenue $638M, consensus $627.4M. “The Exact Sciences team is off to a strong start again in 2024. Our team delivered more than a million Cologuard(R) and Oncotype DX(R) test results to patients and advanced our deep pipeline of life-changing cancer diagnostics,” said Kevin Conroy, chairman and CEO. “As we expand our portfolio globally, our seamless customer experience, powerful commercial engine, and high-quality lab and technology foundation will continue to gain momentum, supporting our mission to help eradicate cancer.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- EXAS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Baird says FDA final LDT rule favorable for Life Sciences, Diagnostics coverage
- Exact Sciences Announces Board Member Retirement
- Exact Sciences CFO’s resume ‘impressive,’ says William Blair
- Exact Sciences Appoints Aaron Bloomer as New CFO